Kurma Partners closed a €215 million fund, its fourth and largest, targeting investments in “disruptive therapeutic solutions.” The venture capital firm framed the new vehicle around expanding its capacity for early and growth-stage bets across biotech themes, citing prior exits including acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma. A fund close of this size can signal sustained institutional appetite for venture-backed drug development, particularly when investors expect differentiation from platform and clinical-stage de-risking. Kurma’s commitment now places additional capital in the pipeline at a time when biotech dealmaking increasingly clusters around late-stage execution and clear clinical development catalysts.